Meridian wins FDA clearance
for new campylobacter test
Source of Article: http://www.tradingmarkets.com/.site/news/Stock%20News/2161541/
Thu. February 05, 2009; Posted: 09:35 AM
Feb 05, 2009 (Datamonitor via
COMTEX) -- -- Meridian Bioscience, a fully integrated life science company,
has received the FDA clearance for a new test for Campylobacter. Launched as
Premier Campy, the rapid enzyme immunoassay test provides for optimized
detection of Campylobacter infection, the company said.
According to the company, there is a significant need for the Premier
Campy test because it provides a solution to several concerns associated with
culture testing, currently the most commonly practiced lab technique for
detecting the campylobacter bacteria.
Premier Campy dramatically reduces these concerns with a
consistent enzyme immunoassay method that measures the antigen instead of the
fragile bacteria in an environment that is less inhibitory than current
culturing procedures, the company claimed.
John Kraeutler, CEO of Meridian,
said: "This new assay solidifies our position as a leader in rapid,
accurate testing methods in food borne testing. Premier Campy is already in
distribution via Meridian Bioscience Europe for the company's European
markets and was also recently approved for sale in Canada."
Republication or redistribution, including by framing or
similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in
the content, or for any actions taken in reliance thereon
For full details on Meridian
Bioscience Inc (VIVO) click
here. Meridian Bioscience Inc (VIVO) has Short Term PowerRatings
of 2. Details on Meridian Bioscience Inc (VIVO) Short Term PowerRatings is available at This Link.